217 related articles for article (PubMed ID: 29749483)
1. Integrated bioinformatics analysis reveals that the expression of cathepsin S is associated with lymph node metastasis and poor prognosis in papillary thyroid cancer.
Tan J; Qian X; Song B; An X; Cai T; Zuo Z; Ding D; Lu Y; Li H
Oncol Rep; 2018 Jul; 40(1):111-122. PubMed ID: 29749483
[TBL] [Abstract][Full Text] [Related]
2. Identification of biomarkers associated with cervical lymph node metastasis in papillary thyroid carcinoma: Evidence from an integrated bioinformatic analysis.
Zhang Z; Zhao S; Wang K; Shang M; Chen Z; Yang H; Chen Y; Chen B
Clin Hemorheol Microcirc; 2021; 78(2):117-126. PubMed ID: 33554894
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of MEDAG gene expression in papillary thyroid microcarcinoma: associations with histological features, regional lymph node metastasis and prognosis.
Song Y; Fu LJ; Li HT; Qiu XG
Sci Rep; 2019 Apr; 9(1):5800. PubMed ID: 30967566
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of miR‑486‑5p in papillary thyroid carcinoma tissue: A study based on microarray and miRNA sequencing.
Wen DY; Pan DH; Lin P; Mo QY; Wei YP; Luo YH; Chen G; He Y; Chen JQ; Yang H
Mol Med Rep; 2018 Sep; 18(3):2631-2642. PubMed ID: 30015845
[TBL] [Abstract][Full Text] [Related]
5. Integrated bioinformatics analysis of the association between apolipoprotein E expression and patient prognosis in papillary thyroid carcinoma.
Jiang Q; Feng W; Xiong C; Lv Y
Oncol Lett; 2020 Mar; 19(3):2295-2305. PubMed ID: 32194729
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of novel long intergenic non‑coding RNA LINC02454 is associated with a poor prognosis in papillary thyroid cancer.
Tan J; Liu L; Zuo Z; Song B; Cai T; Ding D; Lu Y; Ye X
Oncol Rep; 2020 Oct; 44(4):1489-1501. PubMed ID: 32945494
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of extranodal extension of regional lymph node metastasis in papillary thyroid cancer.
Wu MH; Shen WT; Gosnell J; Duh QY
Head Neck; 2015 Sep; 37(9):1336-43. PubMed ID: 24821456
[TBL] [Abstract][Full Text] [Related]
8. Prediction Biomarkers Associated with Lymph Node Metastasis and Prognosis were Identified in Papillary Thyroid Carcinoma via Integrated Bioinformatics Analysis.
Gan S; Ye R; Ha Y; Xiong Y; Li R; Di X; Zou Z; Sun Y; Zhang Z
Comb Chem High Throughput Screen; 2021; 24(9):1395-1409. PubMed ID: 33155892
[TBL] [Abstract][Full Text] [Related]
9. The Value of Ki-67 Labeling Index in Central Lymph Node Metastasis and Survival of Papillary Thyroid Carcinoma: Evidence From the Clinical and Molecular Analyses.
Lei Y; Zhao X; Feng Y; He D; Hu D; Min Y
Cancer Control; 2023; 30():10732748231155701. PubMed ID: 36744396
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic and prognostic value of tumor-infiltrating B cells in lymph node metastases of papillary thyroid carcinoma.
Yang Z; Yin L; Zeng Y; Li Y; Chen H; Yin S; Zhang F; Yang W
Virchows Arch; 2021 Nov; 479(5):947-959. PubMed ID: 34148127
[TBL] [Abstract][Full Text] [Related]
11. IGFBP3 as an indicator of lymph node metastasis and unfavorable prognosis for papillary thyroid carcinoma.
Huang Y; Chang A; Zhou W; Zhao H; Zhuo X
Clin Exp Med; 2020 Nov; 20(4):515-525. PubMed ID: 32596748
[TBL] [Abstract][Full Text] [Related]
12. TPO as an indicator of lymph node metastasis and recurrence in papillary thyroid carcinoma.
Li X; Cheng R
Sci Rep; 2023 Jul; 13(1):10848. PubMed ID: 37407700
[TBL] [Abstract][Full Text] [Related]
13. Identification of gene co-expression modules and hub genes associated with lymph node metastasis of papillary thyroid cancer.
Zhai T; Muhanhali D; Jia X; Wu Z; Cai Z; Ling Y
Endocrine; 2019 Dec; 66(3):573-584. PubMed ID: 31332712
[TBL] [Abstract][Full Text] [Related]
14. Investigation of the prognosis of patients with papillary thyroid carcinoma by tumor size.
Ito Y; Fukushima M; Kihara M; Takamura Y; Kobayashi K; Miya A; Miyauchi A
Endocr J; 2012; 59(6):457-64. PubMed ID: 22447137
[TBL] [Abstract][Full Text] [Related]
15. Competing endogenous RNA regulatory network in papillary thyroid carcinoma.
Chen S; Fan X; Gu H; Zhang L; Zhao W
Mol Med Rep; 2018 Jul; 18(1):695-704. PubMed ID: 29767230
[TBL] [Abstract][Full Text] [Related]
16. Risk of recurrence in a homogeneously managed pT3-differentiated thyroid carcinoma population.
Chereau N; Dauzier E; Godiris-Petit G; Noullet S; Brocheriou I; Leenhardt L; Buffet C; Menegaux F
Langenbecks Arch Surg; 2018 May; 403(3):325-332. PubMed ID: 29445865
[TBL] [Abstract][Full Text] [Related]
17. Association between the HLA-G molecule and lymph node metastasis in papillary thyroid cancer.
Nunes LM; Ayres FM; Francescantonio IC; Saddi VA; Avelino MA; Alencar Rde C; Silva RC; Meneghini AJ; Wastowski IJ
Hum Immunol; 2013 Apr; 74(4):447-51. PubMed ID: 23261411
[TBL] [Abstract][Full Text] [Related]
18. Restratification of survival prognosis of N1b papillary thyroid cancer by lateral lymph node ratio and largest lymph node size.
Kim HI; Kim TH; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Jang HW; Kim YN; Kim H; Ahn HS; Kim K; Kim SW; Chung JH
Cancer Med; 2017 Oct; 6(10):2244-2251. PubMed ID: 28857489
[TBL] [Abstract][Full Text] [Related]
19. Network-based meta-analysis in the identification of biomarkers for papillary thyroid cancer.
Zhao H; Li H
Gene; 2018 Jun; 661():160-168. PubMed ID: 29625265
[TBL] [Abstract][Full Text] [Related]
20. Clinical risk factors associated with cervical lymph node recurrence in papillary thyroid carcinoma.
Baek SK; Jung KY; Kang SM; Kwon SY; Woo JS; Cho SH; Chung EJ
Thyroid; 2010 Feb; 20(2):147-52. PubMed ID: 19785522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
